Epicept - a pain CO with tree supportive cancer legs?
I could not help woundering over the repeated mentioning in the Edison analysis of an out licening of the US market for Ceplene after a SPA-protocol with the FDA. Have the new data from the CIPN diagnosis for Amiket given the board of Epicept a new strategy where the three cancer legs will support the way to a pain approach for Epicept, going for the phase three alone?
A 25-30% royalty for Ceplene in the US plus 60-80 MUSd in upfront followed by a NCI financed phase III for Amiket holding the future open of the best way of navigating when the results is there, what is that?
Reduction of risk, securing income and keeping enormous income possible via Amiket?
Maybe there are several ways to the market given the judge market of 15 milj pts in two years?
May I give you one suggestion? Forget talking about what will happen about EPCT as a company, just "guess" what willhappen about EPCT as a stock, after all you either make or lose money based on the stock price, so far, if you look at the stock charts, one month, one year, three year, five year ...
>Larsyboy, no sense to take you serious. you are known that you have no clue about nothing. If you are paid by a dime, you sell every nonsense. Be happy, your fate is born stupid and dying even dumber<.
This boy must have a wind-up toy which gives him his abstruse numbers